Almost a year after announcing its intention to acquire a majority stake in M.I.Tech, the South Korean medtech responsible for a portfolio of gastrointestinal and airway stents, Boston Scientific is walking away from the deal.
In a statement sent to Fierce Medtech on Thursday, Boston Scientific said the agreement “required global regulatory approvals that we were not able to obtain in some countries.”